Whitman and Myers [70] also recommended a repeat polysomnogram at 3–6 months after the initiation of GH in patients with PWS previously diagnosed and treated for OSA as well as regular screening with the Chervin sleep questionnaire (questions 1–6), examination of the oropharynx for tonsillar hypertrophy and monitoring of IGF-1 levels during the entirety of GH therapy. This evidence concerns the gene GH1 and Prader-Willi syndrome.